Sarah Snykers PhD

Sarah is the QC Manager for Celyad. Sarah has over 10 years of experience in cell therapy, biomedical research, and development. She is a pharmacist from education and has a PhD in pharmaceutical and biomedical sciences, specialized in stem cell biology. In 2010, she joined Promethera Biosciences, a biopharmaceutical company dedicated to the development of cell therapy products based on allogeneic adult stem cell technology to treat liver diseases. She headed the R&D, QC and Preclinical Departments.

In 2015, she joined Celyad, a biopharmaceutical company, specialised in autologous and allogeneic cell therapy. Celyad’s core business lies in the field of immune-oncology, and more specifically the development of NK-receptor-based CAR T therapies. Sarah initially led the immune-oncology program at the R&D level, focused on technology transfer, product characterization, and optimization. Since 2016, she heads the QC Department, covering the release of clinical products and raw materials, analytical method development, and translational research activities.